Phase IIb trial comparing two concurrent cisplatin schedules in locally advanced head and neck cancer
Background: Concurrent chemoradiation with 3 weekly cisplatin (100 mg/m2) is the standard of care for locally advanced head and neck cancer. However, this regimen has been shown to be associated with lesser compliance and higher toxicities. Hence, there is a need to explore alternative concurrent ci...
Main Authors: | Lekha Madhavan Nair, R Rejnish Kumar, Kainickal Cessal Thomachan, Malu Rafi, Preethi Sara George, K M. Jagathnath Krishna, Kunnambath Ramadas |
---|---|
Format: | Article |
Language: | English |
Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2017-01-01
|
Series: | South Asian Journal of Cancer |
Subjects: | |
Online Access: | http://journal.sajc.org/article.asp?issn=2278-330X;year=2017;volume=6;issue=2;spage=64;epage=68;aulast=Nair |
Similar Items
-
Efficiency of Cisplatin Based Concurrent Chemoradiation in Stages III & IV Head & Neck Squamous Cell Carcinoma
by: Kulsoom Begum, et al.
Published: (2016-08-01) -
A comparative study on weekly versus three weekly cisplatin based concurrent chemoradiotherapy in treatment of carcinoma cervix; Patient compliance and Feasibility study
by: Dr. Pranabandhu Das, et al.
Published: (2019-09-01) -
Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin
by: Maurice J. D. L. van der Vorst, et al.
Published: (2019-11-01) -
Primary chemoradiation with cisplatin versus cetuximab for locally advanced head and neck cancer: a retrospective cohort study
by: Il Seok Daniel Jeong, et al.
Published: (2020-08-01) -
Conventional chemoradiation with Cisplatin Versus hemoradiation with Cisplatin plus Gemcitabine in uterine cervical cancer
by: Ahmad Ameri (MD), et al.
Published: (2008-10-01)